



h

h

h

h

h

h

h

h

h

h

h 2011

I have been

in

at

all

me

balance

is

he

generic group

etc

the first

best

in

with the

second

p

but

it may be

change in

in the hospital and in the

and p

he can't

wait

The group

p

in the

6

he is

is a

mf

of the

is a

either

because

by

p

it

it is

the

it is

we

Where

has

we

of

we

is

see

My

he

if

it

it is

we

f

it is

to

p

p

A

One litigant at a time will be the

the Eleventh Circuit *FTC v. Watson*

*Pharmaceuticals, Inc.*,<sup>1</sup> between *AndroGel* and which

and 01 p TH

6 n. 1. If the defendant is a

but also p

the *NO GEL*; there had been

slies *Pharmaceuticals* *Pharmaceuticals* Pa

*Pharmaceuticals* <sup>2</sup>

This *Pharmaceuticals* *Pharmaceuticals* *Pharmaceuticals*

will review brief beef ly it may

*NO GEL* in the *Pharmaceuticals* *Pharmaceuticals*

in the *Pharmaceuticals* S

f <sup>3</sup> *Pharmaceuticals* *Pharmaceuticals* *Pharmaceuticals*

patent infringement NO. 09-1474 Pa

became a trademark of the defendant

the defendant 5

The Commission 2009

challenge

the defendant, the plaintiff

6 The defendant established

the Commission's high

the defendant's I believe the Commission

the defendant's 7

In my view of the defendant's

of the defendant *Schering-Plough Corp. v. FTC*<sup>8</sup>

the defendant's 8 the defendant's

9 The defendant's *Schering-*

*Plough*

comp

0 it

is: en the El eoh Critf

hi en tssah the b

the p

hys6

he f

el ag tchal egedst enen

deci hering fa on

suighen

<sup>1</sup> Ther ap

he d sctctop

htsiral ith dast gna

enverok ing he si

f

comp

ap

the tre p

Rue 8 6

he wa Rues6

P con <sup>2</sup> in *Bell Atlantic Corp. v. Twombly.*<sup>3</sup> Other *Schering-Plough*

n *Valley Drug* abe f

ing hei ghly Maclua

o

p

I ded

he El eoh Critic f

*Andrx*

nhisl ean

*Pharmaceuticals, Inc. v. Elan Corp.*<sup>4</sup> I nra he ct6

p

rethe d sctct6

atrcil si ap

<sup>0</sup> See J.

d am

Pyf

Thm Res,

o the f enen

cap

ehly ~~ates~~

at

si ~~che p~~

di ~~bits~~

cap

1

At ~~ly~~

ahgh i ~~ef~~

*Schering-Plough* ~~tsa id, erche~~

he

p

~~one~~ he ~~sub~~ in

igenen

idity

df

litna yφ



the P

ROVIGIL,

etip

in f

s be generic l er

Lat

In

Lat

In

;



in the p

<sup>3</sup> The c

the RE56

p

3

I n

*Cephalon*

n

f

i

i

b

sp

<sup>3</sup> beca

cal e p

6

l w <sup>6</sup> B

*Cephalon*

at

p

i

p l

he

ice f

enigh

he- p

p

b

<sup>3</sup> B

he i

the

<sup>3</sup> *AdM*

In

MS,

01U

S

available at <http://www.fda.gov/oc/ohrt/066884.pdf>.

s /10066884

g

<sup>3</sup> *Id.*,

01U

S

sp

*Id.* ¶

01U

D

LEXI 9859,

¶.

<sup>3</sup> *See King Drug,*

70F

est

mlp

he l

al e

f f

el i

te righ

erdr

he p

al ege f

ch sp

PTO,

n

)

rgene

P

<sup>6</sup> *See, e.g., Richd ,*

In

v

beig i

inged

<sup>3</sup> *See, e.g., Bf*

6

he Eda T

ing Rea

*In re K- Litg.*

est g f

in gesch del p

f

il sct r p

The p

Denber 6,

01 f

ce tische

f rati

il ig

j gnet r

§ 51 f

de r p

The herca 6

C r i t i s t i n e T h i d

*K-Dur Antitrust Litigation*,<sup>3</sup> wch hbeerschell f

de gnet

erck Denber 2

01

e t n i s r h e p

J s e f

il b e f a i c s b r e f

6 s

Gerh n h e r 6

p

a

Y p

h e a n e p

h e g e d e T h i d i r t t p

37 Mr

6

erl s r b e i d e e k e p

n a i s t p

f

p

Ms,

h e p

t n i t l B e f

*In re K- Dur Litg.*

01 f h e r i f i

s y g h t n e v i d i t g e n

s i c t r a p

i g a t t e r i e n b e h e r t p

Ms,

f

01 f h e r i f i

de l i d e s

, p

ighf

legah if

asg he tncp

p

4

x Thp  
subject

2

litra b e t r 6

p

h a m p

I n i s m a r

h e t t e h e - 6

- e s p

p

ä t f

f

h a

h e p

a i d t y p

f

ö d l y s t i n f e r e n s b l e,

n ä,

i l

g r e n s l i n e n s b e c k

i d e t h e r y p

h e r h a

d f

e d t y p

e t t b e e t t

d i r y g h e i r e t e n s b y m i g f

d i n e i d r e l g e l y r h e i r

e s t i s p

We k ä l ä e h e r h e T h i d i r t a r e p

d f

f

s

e c t u s f

C

I h i k i t i s f

f

ä r t h e n

c e n t a l y f

p

g r e s

i n e t g h e H e t h W a n

ä

g h t t s k e d a r e

b e t e n v g i t t y b a f i

e t s f

b l e n

m p

i s h a e i s t e,

h e r

The l e t t e r

p h e p

t g h e p

e t i n s n

e i s m p

e k a m p

likely to

p

7

design

he p

p

8

likely

while it

is in the

likely

total

entire

to be

is that there

litigation

which is

f

P

total

initial

the entire

in the litigation

That the

Hebrew

9

A

the

total

the

entire

entire

the Hebrew

and

initial

the entire

of

7 G

the

the

the

P

the

the

the

the likely

the

the

8 U

)

(i)(2) of S

the

the

the

the

if

See U

the

(i)(2)

S

9 See the P

the

the

the

In re

the

the

6,





its

he can see the light

the Part of

f

ice.

I ep

he p

g he g n be c n r e

its

he sp ich ita

mp

tcl e n yel d n o

he ep

g the l g e d n o

he

tel amp

isp

tsir be n o

he g n

i.

e.

he g n

h d n r

o j g c n r o l l e t r o

emp

cl d s s c d s h t a p

tk he p

<sup>54</sup> the by

l g i c h n e t a g e r i c d f

l i d i a l e n d f

6

sek sh el ief

6 isif

f i t w e k i n g o

f

mp e d n d o

is g h e g n a

hp

55

This

erif

ap

nehA

erif d n l l b e p p

tel amp

h i c h h e g e r i c e r o d e

U

available at [hp](http://)

S

p

84p

rebrief

54 2J

S

55 2J

(ii) (0)

S

in fact <sup>56</sup> Others,

he exp

he P pp

is to be had

I might not of

if

nois stop p a

l exp

e g

he exp

his interview

tt of

he p

mh of

<sup>57</sup>

is he g

He had

Let me see what he p

p

have of

henki g al al e the Cui so

A

We exp

p

f

<sup>58</sup> The f

edl yet ems

its in S 1 2

kol

<sup>56</sup> Of  
to be con p

cs  
but et ch eger

if

ap

<sup>57</sup> Here the f  
con amp

al ey the exp

*If a patent does not claim an approved method of using the drug, then correction or deletion is required.*

by the Kbl Ga

by Pres AestA

f

59

I taido Jst,

01

erp

com te vnto doly2

01

882

kulf

she Bgali trm

erdyne

I meda Rel ea 6

<sup>60</sup> Gaido GA

erb

com te rdbert,

01

The Kbl Geybill ep

icup

ep

st enst

<sup>61</sup> svl stoge inl tchenig

<sup>62</sup> A hwp

td

63



6      ~~fero~~      ~~erif~~      p      ~~he st ent~~  
p      ~~tdde~~ by

based in generic f

il en v ap

il tct to stuf

ti fi op

igen th y e b ap

B

I ha gget di ne p

al hl e the Cui s ob di tef

f

is the ct of

gest p

<sup>74</sup> the p

p

<sup>75</sup> Birt ch e ad g u e s

gath is the,

twich I w t ap

ht en ki g u be imp

ris th is p

6

th is h d h c s i the

ct of

<sup>76</sup> h e g u e t i s h e g u e t i g u d o

th

---

<sup>73</sup> AR Gerics Af g

*supra* t 72

judicially

essential

77

Here is

has been

§

he is

df

ing

f

78

is

emp

idp

p

79

§ 6

80

he is

The D

C

§ 6

emp

§ 6

81

Rlenig

§ 6

§ 6

77

supra

he is

light

§ 6

with

bioRxiv preprint doi: <https://doi.org/10.1101/2017.07.27.181111>; this version posted August 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

abp



Imp

Chevron,<sup>86</sup> ~~the~~ ~~imp~~ ~~of~~

ere the ~~mi~~ ~~sa~~

hen ~~g~~ ~~sc~~ ~~i~~ ~~t~~ ~~d~~ ~~i~~ ~~l~~ ~~e~~ ~~r~~ ~~a~~

ei ~~ri~~ ~~ch~~ ~~g~~ ~~r~~ ~~s~~ ~~e~~ ~~p~~

l ef

<sup>87</sup> ~~It~~ ~~g~~ ~~e~~ ~~a~~ ~~s~~

p

th ~~y~~ ~~e~~ ~~g~~ ~~r~~ ~~e~~ ~~s~~ ~~i~~ ~~l~~ ~~e~~ ~~g~~ ~~r~~ ~~a~~ ~~t~~ ~~i~~ ~~o~~ ~~n~~

l egi ~~s~~ ~~l~~ ~~e~~ ~~g~~ ~~i~~ ~~s~~ ~~i~~ ~~o~~ ~~n~~

ar

nd ~~e~~ ~~s~~

mp

A

b ~~t~~ ~~a~~ ~~s~~ ~~i~~

the ~~H~~ ~~e~~ ~~l~~ ~~e~~ ~~w~~ ~~e~~ ~~r~~ ~~l~~ ~~i~~ ~~c~~ ~~h~~

ce ~~n~~ ~~t~~ ~~p~~

p

<sup>88</sup> ~~the~~ ~~M~~ ~~i~~ ~~l~~ ~~c~~ ~~a~~

P ~~e~~ ~~s~~ ~~i~~ ~~p~~

p

mp

f

<sup>89</sup>

il ~~e~~ ~~d~~ ~~i~~ ~~t~~ ~~e~~

g ~~o~~ ~~u~~ ~~t~~ ~~h~~ ~~e~~ ~~g~~ ~~i~~ ~~s~~ ~~i~~ ~~n~~ ~~g~~ ~~6~~

p

ac ~~e~~ ~~s~~ ~~i~~ ~~s~~ ~~t~~ ~~r~~ ~~a~~ ~~d~~ ~~e~~ ~~n~~

dat ~~i~~ ~~n~~ ~~g~~ ~~r~~ ~~e~~ ~~c~~ ~~e~~ ~~d~~

p

<sup>86</sup> ~~the~~ ~~U~~

g

S ~~e~~ ~~n~~ ~~s~~ ~~i~~ ~~t~~ ~~i~~ ~~l~~ ~~,~~

I ~~n~~

<sup>87</sup> ~~Id.~~ ~~8~~ ~~4~~ ~~f~~

g ~~r~~ ~~s~~ ~~e~~ ~~p~~

ep

agi ~~o~~ ~~r~~ ~~a~~ ~~b~~ ~~i~~ ~~g~~ ~~n~~ ~~i~~ ~~g~~ ~~h~~ ~~t~~ ~~e~~ ~~s~~ ~~e~~ ~~y~~

h ~~e~~ ~~l~~ ~~e~~ ~~g~~ ~~i~~ ~~s~~ ~~i~~ ~~v~~ ~~e~~ ~~r~~ ~~a~~ ~~t~~ ~~i~~ ~~o~~ ~~n~~

es ~~i~~ ~~l~~ ~~e~~ ~~g~~

by ~~g~~ ~~l~~ ~~a~~ ~~n~~

cp

l ~~y~~ ~~e~~ ~~t~~ ~~a~~

See ~~also~~ ~~FC~~ ~~v~~

)

P ~~a~~ ~~n~~ ~~b~~ ~~i~~ ~~v~~ ~~6~~

th ~~e~~

re ~~p~~ ~~u~~ ~~b~~ ~~l~~ ~~i~~ ~~c~~ ~~h~~ ~~e~~  ~~[~~ ~~8~~ ~~9~~ ~~U~~

j ~~u~~ ~~n~~ ~~i~~ ~~s~~ ~~t~~ ~~e~~ ~~g~~ ~~i~~ ~~n~~ ~~t~~ ~~a~~ ~~i~~ ~~g~~ ~~h~~ ~~t~~ ~~e~~ ~~s~~ ~~e~~ ~~y~~ ~~s~~ ~~e~~ ~~c~~ ~~t~~ ~~s~~

)

<sup>88</sup> ~~2~~ ~~5~~ ~~5~~ ~~(~~ ~~1~~ ~~1~~ ~~)~~ ~~2~~ ~~0~~ ~~(~~ ~~h~~ ~~e~~ ~~F~~

th ~~T~~ ~~e~~ ~~g~~ ~~i~~ ~~s~~ ~~i~~ ~~n~~ ~~g~~ ~~e~~ ~~t~~ ~~y~~

Ge ~~r~~ ~~t~~ ~~f~~

il ~~e~~ ~~s~~ ~~a~~ ~~m~~ ~~p~~

he ~~c~~ ~~t~~ ~~i~~ ~~v~~ ~~e~~ ~~r~~ ~~a~~ ~~t~~ ~~i~~ ~~o~~ ~~n~~

ich ~~o~~ ~~p~~

p

ib ~~e~~ ~~t~~ ~~e~~ ~~s~~ ~~e~~ ~~l~~ ~~f~~

i ~~r~~ ~~e~~ ~~c~~ ~~i~~ ~~t~~ ~~i~~ ~~o~~ ~~n~~

th ~~e~~ ~~l~~

en ~~e~~ ~~f~~

sc ~~r~~ ~~i~~ ~~t~~ ~~i~~ ~~o~~ ~~n~~

th ~~e~~ ~~l~~ ~~e~~ ~~s~~ ~~e~~ ~~p~~ ~~t~~ ~~i~~ ~~o~~ ~~n~~

fi

am ~~a~~ ~~h~~ ~~6~~

es ~~e~~ ~~p~~

mp

eth

<sup>89</sup> ~~M~~ ~~i~~ ~~c~~ ~~a~~ ~~P~~ ~~e~~ ~~s~~ ~~i~~ ~~p~~

I ~~m~~ ~~p~~

N

08- 13

S ~~i~~ ~~6~~ ~~,~~

el ~~i~~ ~~e~~ ~~f~~

f

mp

p

P

fero  
Gni sckenki gif

i tskese harn sbude l esi  
over

relythe

1618

I will p

disc

he miss

ep

gs

including 94 do

efi

ent6 erhe MilcaP esip

he f

I mp

<sup>95</sup> which I will call the MA

f

do

A

no generic head

in the 5

Disc A

of the beer

but get tanked

sd

no generic gs <sup>96</sup> I mp

be l ed by a

d m n

and the 80-

gated ivy

N f

il er

mp

6

6

6

6

6

80- 6

80- 6

97

97

97

97

98

98

98

98

98

98

98

98

98

98

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

99

herbyhngcnd

ih he f

ndtis

N f

illel essrs

ip

ndgeric.

01

the 80- year old

04 With

imp

in the hospital

p

concerning

general

and

in the

of the

and the

in the

05

ins

This is

in the

f

cap

in the 80- year old

I

in the

cap

in the

in the

he p

ger

in the

net

in the

f

in the

in the

ey

in the

I

in the

ef

f in the

ect

in the

al p

04 AUTHORIZ GENERIC DRGS , supra ED

the M...  
 generic...  
 their...  
 generic...  
 he f...  
 The...  
 p...  
 I...  
 he f...  
 ilig...  
 the g...  
 her...  
 the...  
 he...  
 B...

<sup>06</sup> MilcaP...  
 N...  
 r... see...  
 I...  
 T...  
[0/0006p](#)

08- 73 SB  
[http](#) S

<sup>07</sup> See, e.g., F

